Full TitleC1071001: A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of PF-06863135, A B-Cell Maturation Antigen (BCMA)- CD3 Bispecific Antibody, As A Single Agent And In Combination With Either PF-068001591 Or Lenalidomide In Patients With Relapsed/Refractory Advanced Multiple Myeloma (MM)
The purpose of this study is to find the highest dose of the investigational drug PF-06863135 that can be given safely in patients with multiple myeloma that has continued to grow or came back despite prior treatment. PF-06863135 is an antibody that targets a protein on myeloma cells called BCMA as well as a protein on immune cells (T cells) in the body. By bringing these cells together and activating T cells, PF-06863135 is designed to stimulate immune cells to kill cancer cells. PF-06863135 is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have multiple myeloma which has continued to grow or came back despite prior therapy.
- Patients must recover from the serious side effects of previous therapy before entering the study.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients ages 18 to 69.